OmniAb to Report Fourth Quarter 2022 Financial Results on March 30
March 09 2023 - 8:00AM
Business Wire
OmniAb, Inc. (NASDAQ: OABI) will report financial results
for the three and 12 months ended December 31, 2022 after the close
of the U.S. financial markets on Thursday, March 30, 2023 and will
hold a conference call that same day beginning at 4:30 p.m. Eastern
time.
Conference Call and Webcast Information
What:
OmniAb conference call to discuss
financial results and business updates
Date:
Thursday, March 30, 2023
Time:
4:30 p.m. Eastern time (1:30 p.m.
Pacific time)
Conference Call:
U.S. (888) 886-7786
International +1 (416)
764-8658
Conference ID is 43857264
Webcast:
Live and replay webcast of the
call with slides will be available here.
About OmniAb®
OmniAb, Inc.’s discovery platform provides pharmaceutical
industry partners access to diverse antibody repertoires and
high-throughput screening technologies to enable discovery of
next-generation therapeutics. At the heart of the OmniAb platform
is the Biological Intelligence™ (BI) of our proprietary transgenic
animals, including OmniRat®, OmniChicken® and OmniMouse® that have
been genetically modified to generate antibodies with human
sequences to facilitate development of human therapeutic
candidates. OmniFlic® (transgenic rat) and OmniClic® (transgenic
chicken) address industry needs for bispecific antibody
applications though a common light chain approach, and OmniTaur™
features unique structural attributes of cow antibodies for complex
targets. We believe the OmniAb animals comprise the most diverse
host systems available in the industry and they are optimally
leveraged through computational antigen design and immunization
methods, paired with high-throughput single B cell phenotypic
screening and mining of next-generation sequencing datasets with
custom algorithms to identify fully human antibodies with superior
performance and developability characteristics. An established core
competency focused on ion channels and transporters further
differentiates our technology and creates opportunities in emerging
target classes. OmniAb antibodies have been leveraged across
modalities, including bispecific antibodies, antibody-drug
conjugates and others. The OmniAb suite of technologies span from
BI-powered repertoire generation to cutting edge antibody discovery
and optimization offering a highly efficient and customizable
end-to-end solution for the growing discovery needs of the global
pharmaceutical industry.
For more information, please visit www.omniab.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230309005080/en/
OmniAb, Inc. investors@OmniAb.com Twitter @OmniAbTech (510)
250-7801
LHA Investor Relations Yvonne Briggs ybriggs@lhai.com (310)
691-7100
OmniAb (NASDAQ:OABI)
Historical Stock Chart
From Sep 2024 to Oct 2024
OmniAb (NASDAQ:OABI)
Historical Stock Chart
From Oct 2023 to Oct 2024